Apollomics Inc. Secures $2.0 Million Bridge Loan via Convertible Note from CEO
On March 30, 2026, Apollomics Inc. entered into a $2.0 million unsecured convertible promissory note with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen. This related-party transaction provides the company with an unsecured bridge loan bearing 0% interest per annum. The principal amount is set to automatically convert into equity securities upon the closing of the companyβs next equity financing that raises at least $10.0 million in aggregate gross proceeds. The conversion price for such an event is established at 80% of the lowest per-share price paid by investors in that financing. If no conversion occurs within 18 months, the holder may elect to convert the note into Class A ordinary shares based on the 10-day average closing price preceding the maturity date. Apollomics intends to utilize the proceeds for working capital and general corporate purposes to support its ongoing clinical operations, including its lead oncology program, vebreltinib (APL-101). The transaction was approved by the independent Audit Committee and the Board of Directors.